Monopar Therapeutics Inc (NASDAQ:MNPR) — Market Cap & Net Worth
Market Cap & Net Worth: Monopar Therapeutics Inc (MNPR)
Monopar Therapeutics Inc (NASDAQ:MNPR) has a market capitalization of $700.28 Million ($700.28 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10567 globally and #2807 in its home market, demonstrating a -11.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Monopar Therapeutics Inc's stock price $104.33 by its total outstanding shares 6712172 (6.71 Million). Also see how large is Monopar Therapeutics Inc's balance sheet for a full breakdown of the balance sheet.
Monopar Therapeutics Inc Market Cap History: 2019 to 2026
Monopar Therapeutics Inc's market capitalization history from 2019 to 2026. Data shows change from $557.11 Million to $700.28 Million (-3.48% CAGR). Also see Monopar Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Monopar Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.03% | #298 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1093 of 3165 |
Weight: Monopar Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Monopar Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Monopar Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Monopar Therapeutics Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1678.04x
Monopar Therapeutics Inc's market cap is 1678.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $205.39 Million | $122.40K | -$6.30 Million | 1678.04x | N/A |
Competitor Companies of MNPR by Market Capitalization
Companies near Monopar Therapeutics Inc in the global market cap rankings as of September 17, 2026. Review Monopar Therapeutics Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Monopar Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Monopar Therapeutics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Monopar Therapeutics Inc's market cap moved from $557.11 Million to $ 700.28 Million, with a yearly change of -3.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $700.28 Million | +59.77% |
| 2025 | $438.30 Million | +196.82% |
| 2024 | $147.67 Million | +1194.12% |
| 2023 | $11.41 Million | -85.65% |
| 2022 | $79.54 Million | -26.17% |
| 2021 | $107.73 Million | -47.55% |
| 2020 | $205.39 Million | -63.13% |
| 2019 | $557.11 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Monopar Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $700.28 Million USD |
| MoneyControl | $700.28 Million USD |
| MarketWatch | $700.28 Million USD |
| marketcap.company | $700.28 Million USD |
| Reuters | $700.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more